List of Excipients in Branded Drug DIOVAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	DIOVAN	valsartan	0078-0423	CELLULOSE, MICROCRYSTALLINE
Novartis Pharmaceuticals Corporation	DIOVAN	valsartan	0078-0423	CROSPOVIDONE
Novartis Pharmaceuticals Corporation	DIOVAN	valsartan	0078-0423	FERRIC OXIDE YELLOW
Novartis Pharmaceuticals Corporation	DIOVAN	valsartan	0078-0423	HYPROMELLOSES
Novartis Pharmaceuticals Corporation	DIOVAN	valsartan	0078-0423	MAGNESIUM STEARATE

DIOVAN Excipient Strategy and Commercial Opportunities for Valsartan

Last updated: October 14, 2026

Diovan contains valsartan, an angiotensin II receptor blocker used for hypertension, heart failure, and post-myocardial-infarction treatment. Its core composition is no longer protected by meaningful U.S. compound-patent exclusivity, leaving commercial value in differentiated formulations, fixed-dose combinations, pediatric delivery, supply-chain resilience, and regulatory execution rather than in the original tablet formulation.

The most attractive excipient opportunities are lactose-free tablets, lower-cost direct-compression platforms, oral liquids for pediatric and dysphagic patients, improved moisture and impurity control, and fixed-dose combinations with amlodipine, hydrochlorothiazide, or other cardiovascular agents.

What excipients are used in Diovan tablets?

The U.S. Diovan tablet formulation uses conventional solid-dose excipients. The FDA-approved labeling identifies excipient classes that include microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, povidone, talc, titanium dioxide, and colorants. Some strengths also contain lactose and iron oxide-based coloring agents (FDA, 2023).

Diovan excipient profile

Excipient or excipient class	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Supports direct compression and tablet robustness
Lactose	Diluent and bulking agent	Low cost, but creates a lactose-free differentiation opportunity
Crospovidone	Superdisintegrant	Supports rapid tablet breakup
Povidone	Binder	Improves granule and tablet strength
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and processing
Magnesium stearate	Lubricant	Reduces tablet-punch friction
Talc	Processing aid and anti-adherent	Supports manufacturing performance
Titanium dioxide	Opacifier and colorant	Supports product identification and light protection
Iron oxides	Colorants	Enables strength differentiation and brand recognition

The formulation is a conventional immediate-release oral tablet. It does not rely on a novel delivery system, extended-release matrix, lipid carrier, or biologic-compatible excipient platform.

What excipient strategy is most attractive for generic valsartan?

The strongest strategy is a platform approach that reduces manufacturing cost while creating a clinically or operationally useful product distinction.

Lactose-free valsartan tablets

A lactose-free product can target patients with lactose intolerance, hospital formularies seeking simplified excipient declarations, and international markets with different labeling preferences. Lactose substitution could use microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler.

The main development risks are tablet weight, compactability, disintegration time, friability, and dissolution equivalence. A lactose-free formulation must still meet the immediate-release dissolution profile required for an ANDA.

Direct-compression formulation

Direct compression can reduce granulation equipment, solvent use, processing time, and batch complexity. A typical platform would combine:

• Microcrystalline cellulose or a co-processed cellulose excipient as diluent
• Crospovidone or croscarmellose sodium as disintegrant
• Colloidal silicon dioxide as glidant
• Magnesium stearate or sodium stearyl fumarate as lubricant

Valsartan’s powder-flow and compactability characteristics must be controlled because excessive lubricant concentration or mixing time can reduce tablet hardness and slow dissolution. A co-processed excipient may improve manufacturing consistency but can raise material cost.

Low-moisture manufacturing

Valsartan formulations should be evaluated for moisture sensitivity, impurity formation, and stability under accelerated conditions. A low-water process can reduce hydrolytic risk and simplify global distribution. Options include dry granulation, roller compaction, direct compression, high-barrier blister packaging, and desiccant-supported bottle systems.

Moisture control is commercially relevant because valsartan supply chains have faced scrutiny over nitrosamine contamination associated primarily with active pharmaceutical ingredient manufacturing and processing. The 2018 recalls involved N-nitrosodimethylamine and related impurities in valsartan API supplied by certain manufacturers, not a Diovan excipient failure (FDA, 2018).

What formulations are protected by Diovan patents?

The original valsartan composition and Diovan product patents have expired in the United States. The principal U.S. compound patent, U.S. Patent No. 5,399,578, covered valsartan and related compounds. Its effective patent term ended in the early 2010s after accounting for patent-term adjustment and any applicable regulatory extension.

The commercial patent position should be separated into three categories:

Patent category	Diovan relevance	Present commercial impact
Valsartan compound patent	Covered the active molecule	Expired in the United States
Original tablet formulation	Covered conventional pharmaceutical compositions and use	No longer a meaningful barrier to routine generic tablets
Later combinations or delivery systems	May cover specific compositions, combinations, or uses	Potentially relevant only where an unexpired claim remains

A new excipient combination is not automatically patentable. Patent value would require a defensible claim to a composition, process, stability result, dissolution profile, particle-size relationship, or therapeutic use that is non-obvious and adequately supported.

When did Diovan lose exclusivity?

Diovan lost effective U.S. market exclusivity after valsartan’s compound patent expired and FDA-approved generic products entered the market. The FDA approved the first generic valsartan applications in 2012, with multiple manufacturers subsequently receiving approval for valsartan tablets and valsartan/hydrochlorothiazide products (FDA, Drugs@FDA).

U.S. exclusivity timeline

Milestone	Approximate timing	Commercial effect
Valsartan compound patent filed	Early 1990s	Established originator protection
Diovan FDA approval	1996	Commercial launch of valsartan
U.S. pediatric exclusivity period	2006	Temporarily extended regulatory protection
Compound-patent protection ended	Early 2010s	Opened market to generic valsartan
Generic valsartan approvals	2012 onward	Rapid price and share erosion
Nitrosamine-related valsartan recalls	2018 onward	Created supplier qualification and trust concerns

Diovan’s original regulatory exclusivity is no longer a material commercial defense. The product’s continuing value is based on physician familiarity, hospital procurement history, combination products, and international brand presence.

What is the Orange Book status of Diovan?

Diovan and related valsartan products have historically been listed in the FDA Orange Book, but the principal compound protection is expired. Generic applicants have relied on abbreviated new drug application pathways, including paragraph IV certifications where relevant listed patents existed during the approval period.

For a current transaction or launch decision, the relevant inquiry is product-specific:

1. Whether the reference listed drug remains the active reference product for the target dosage form.
2. Whether any unexpired formulation or method-of-use patent is listed.
3. Whether the proposed label carves out protected indications.
4. Whether the applicant must provide a paragraph IV notice.
5. Whether an authorized generic or first-filer status affects launch economics.

The practical Orange Book risk for standard valsartan tablets is low compared with drugs that retain active composition-of-matter or complex-device patents.

Which companies challenged Diovan patents?

Multiple generic companies entered valsartan after the relevant U.S. patent barriers expired or were resolved. Generic valsartan has been marketed by large and mid-sized manufacturers, including Teva, Mylan, Solco Healthcare, Torrent Pharmaceuticals, Alembic, Lupin, and others over different periods and dosage strengths.

The principal competitive issue was not a sustained patent blockade. It was the timing of ANDA approvals, first-filer rights, manufacturing capacity, API availability, and later supply disruption linked to contaminated valsartan API.

Paragraph IV and litigation exposure

Paragraph IV exposure was most relevant before compound-patent expiry. Once the primary patent barrier expired, the litigation value of standard tablet formulations declined sharply. New applicants pursuing conventional valsartan tablets generally face greater regulatory and commercial risks than patent risks.

Potential litigation could still arise from:

• A new fixed-dose combination
• A novel pediatric liquid
• A controlled-release or multiparticulate formulation
• A formulation with a specific impurity-control profile
• Trade-secret misuse involving manufacturing parameters
• ANDA-related allegations concerning a later-listed patent

How strong is the Diovan patent estate?

The patent estate is weak for conventional immediate-release valsartan tablets and stronger only for genuinely differentiated follow-on products.

Asset type	Patent strength	Reason
Conventional valsartan tablet	Low	Active ingredient and basic product protection have expired
Lactose-free tablet	Low to moderate	Patentability depends on unexpected technical performance
Improved stability formulation	Moderate	Stronger if supported by comparative data
Pediatric oral liquid	Moderate	Can support composition and use claims
Fixed-dose combination	Moderate	Depends on prior art and claim scope
Novel delivery system	Moderate to high	Potentially valuable if clinically or technically differentiated
Manufacturing process	Moderate	Requires reproducible, non-obvious process advantages

A formulation patent supported only by routine excipient substitution is vulnerable to obviousness challenges. Commercially useful claims should link the excipient system to measurable results such as improved dissolution after storage, reduced impurity formation, lower tablet-failure rates, or enhanced dose uniformity.

What commercial opportunities exist for Diovan excipient innovation?

Pediatric valsartan oral liquid

A ready-to-use oral liquid would address pediatric and dysphagia use cases. Valsartan has pediatric labeling for hypertension, but conventional tablets can create administration barriers for younger patients.

The formulation would need to manage:

• Poor aqueous solubility
• Palatability
• Dose uniformity
• Preservative selection
• Sedimentation or physical stability
• Container compatibility
• In-use shelf life

Potential excipient systems include suspending agents, wetting agents, sweeteners, flavor systems, buffers, and preservatives. A powder-for-reconstitution product may offer better stability than a ready-to-use liquid and lower shipping weight.

Valsartan fixed-dose combinations

Combination products remain commercially relevant because hypertension treatment commonly uses more than one agent. Opportunities include:

• Valsartan/amlodipine
• Valsartan/hydrochlorothiazide
• Valsartan/amlodipine/hydrochlorothiazide
• Valsartan with other antihypertensive classes

Combination products create excipient challenges because each active ingredient can have different dissolution, pH, moisture, and compression requirements. Bilayer tablets, separate granules, or multilayer manufacturing can provide better control than a single homogeneous blend.

Senior-friendly and dysphagia-focused tablets

Small, low-force, rapidly disintegrating tablets can improve administration without requiring a new therapeutic indication. ODT or orally dispersible formats may be useful, but the excipient system must overcome valsartan’s taste and dose-load constraints.

Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers are potential components. A high-dose ODT may become too large or fragile, limiting commercial practicality.

Global supply-chain formulation

A formulation designed around widely available excipients can reduce dependence on one supplier. Dual-source qualification for microcrystalline cellulose, crospovidone, colloidal silicon dioxide, and lubricants can reduce disruption risk.

The 2018 valsartan recalls showed that API vendor qualification is more commercially important than marginal tablet-cost optimization. A robust product strategy should combine excipient flexibility with multi-source API qualification, analytical nitrosamine controls, and documented change-control procedures (FDA, 2018).

How does Diovan compare with competing ARB products?

Valsartan competes with losartan, irbesartan, candesartan, olmesartan, and telmisartan. All are generic or largely generic in major markets, so excipient differentiation is more important than molecule-level exclusivity.

Product	Active ingredient	Differentiation opportunity
Diovan	Valsartan	Pediatric liquid, combinations, low-moisture tablet
Cozaar	Losartan	Low-cost tablet and combination products
Avapro	Irbesartan	Tablet simplicity and global sourcing
Atacand	Candesartan cilexetil	Solubility and dissolution optimization
Benicar	Olmesartan medoxomil	Combination products and tablet performance
Micardis	Telmisartan	High-dose tablet and fixed-dose combinations

Valsartan has a favorable commercial platform because it is used across hypertension, heart failure, and post-myocardial-infarction indications. Its formulation challenge is less about novel delivery than about dose size, dissolution, taste, and reliable global supply.

What generic launch risks exist for valsartan?

The principal launch risks are regulatory and operational.

Regulatory risks

An ANDA applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. Key controls include assay, content uniformity, dissolution, degradation products, impurities, stability, and manufacturing reproducibility.

A new formulation that changes excipient composition substantially may require additional development work, especially if it changes dissolution or absorption. A liquid, ODT, or modified-release product may require a different regulatory pathway from a standard tablet ANDA.

Manufacturing risks

Valsartan tablets can be exposed to:

• Poor powder flow
• Over-lubrication
• Tablet capping or friability
• Dissolution drift
• Moisture-related degradation
• Color or coating variability
• API particle-size variation

These risks favor a design-of-experiments program that evaluates excipient grade, lubricant level, blending time, compression force, coating conditions, and packaging configuration.

Commercial risks

Generic valsartan is a price-competitive market with numerous suppliers. A new entrant needs a specific advantage, such as:

• Reliable supply during shortages
• A pediatric dosage form
• A lactose-free or allergen-controlled product
• A differentiated combination tablet
• Better hospital packaging
• Lower total manufacturing cost
• A region-specific formulation compliant with local excipient preferences

What licensing opportunities exist around Diovan formulations?

Licensing opportunities are more likely in formulation technology than in the Diovan brand or valsartan molecule. Attractive targets include:

1. Pediatric liquid or powder-for-reconstitution technology.
2. Taste-masking systems for high-dose ARB formulations.
3. Co-processed excipients that improve direct compression.
4. Packaging and moisture-control systems.
5. Fixed-dose combination manufacturing platforms.
6. Analytical methods for nitrosamine and degradation-product control.
7. Regional rights for branded generic or hospital-focused products.

A license should be valued against the low price of standard valsartan tablets. Premium economics require a protected formulation, a regulatory advantage, a supply shortage position, or a product that addresses an underserved administration need.

Key Takeaways

• Diovan’s active ingredient is valsartan, an established generic ARB with expired core U.S. patent protection.
• The original product relies on conventional tablet excipients, including cellulose-based diluents, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, and colorants.
• Standard valsartan tablets offer limited patent value and intense price competition.
• The strongest excipient opportunities are lactose-free tablets, pediatric liquids, taste-masked products, fixed-dose combinations, and low-moisture manufacturing platforms.
• Formulation patents require technical evidence, not routine excipient substitution alone.
• Nitrosamine control, API sourcing, and supply continuity are central commercial risks.
• A differentiated product needs a regulatory, manufacturing, or patient-use advantage to justify premium pricing.

FAQs

Can a lactose-free valsartan tablet receive patent protection?

Yes, but lactose substitution alone may be obvious. Stronger protection would require unexpected dissolution, stability, compression, impurity-control, or patient-use results.

Is Diovan still protected by patents in the United States?

The principal valsartan compound protection has expired. Standard immediate-release valsartan tablets generally face low patent risk, although product-specific listings must be checked for any later patents.

Is valsartan suitable for an oral suspension?

Yes. A suspension can address pediatric and dysphagia markets, but solubility, taste, sedimentation, dose uniformity, preservative effectiveness, and in-use stability require dedicated development.

Can excipients reduce valsartan nitrosamine risk?

Excipient selection can support moisture and stability control, but the primary nitrosamine risk in the 2018 recalls involved contaminated valsartan API and manufacturing processes. API qualification and analytical controls remain central.

Which valsartan product has the best commercial opportunity?

A differentiated pediatric liquid, powder-for-reconstitution product, or fixed-dose combination generally offers more opportunity than another conventional tablet because standard valsartan tablets are widely available and price-competitive.

References

1. U.S. Food and Drug Administration. (2018). FDA updates and press announcements on valsartan, losartan, and irbesartan product recalls. https://www.fda.gov
2. U.S. Food and Drug Administration. (2023). Diovan (valsartan) prescribing information. https://www.accessdata.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov
5. United States Patent and Trademark Office. (1995). U.S. Patent No. 5,399,578: N-substituted derivatives of amino acids. https://patents.google.com/patent/US5399578A